{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-012664","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.117734+00:00","generated_at":"2026-05-16T10:25:51.206998+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sana: UP421 survives 12 months in T1D with no immunosuppression; plans SC451 IND, SG293 data in 2026","bullets":["UP421, a hypoimmune pancreatic islet cell therapy, continued to survive and function at 12 months post-transplant in a T1D patient with no immunosuppression.","On track to file an IND and begin Phase 1 trial for SC451, an iPSC-derived islet cell therapy, as early as 2026.","Goal to generate initial human data in 2026 for SG293, an in vivo CD19-directed CAR T cell therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-012664","json":"https://secwatch.observer/filing/0001193125-26-012664.json","markdown":"https://secwatch.observer/filing/0001193125-26-012664.md","text":"https://secwatch.observer/filing/0001193125-26-012664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526012664/0001193125-26-012664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526012664/sana-20260114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:25:51.206998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}